Humana Inc. (NYSE: HUM) signed a definitive agreement to divest its minority interest in Gentiva to a consortium of investors for approximately $900 million, according to a company statement.

The transaction involves all or substantially all of Humana's minority stake in Gentiva, described as the nation's leading provider of end-of-life services, including hospice and palliative care. The Louisville-based health insurer plans to use proceeds for general corporate purposes.

The sale is expected to close in the third quarter of 2026, subject to regulatory approvals and customary closing conditions. Humana stated it does not anticipate a material impact to 2026 earnings from the pending transaction.

Humana's ownership in Gentiva originated from its 2021 acquisition of the remaining interest in Kindred at Home (KAH). At that time, the company indicated plans to divest non-core KAH businesses, including hospice, palliative, and personal health care services.

In 2022, Humana agreed to sell a majority interest in the Hospice and Personal Care divisions of KAH to private investment firm Clayton, Dubilier & Rice. These divisions were restructured into a standalone business and rebranded as Gentiva, which now operates at more than 430 locations across 35 states.

Guggenheim Securities, LLC is serving as financial advisor to Humana. Fried, Frank, Harris, Shriver & Jacobson LLP and Manatt, Phelps & Phillips LLP are acting as legal advisors.